The effectiveness of CAR T cell therapy against a variety of cancers, including solid tumors, could be boosted greatly by using CRISPR-Cas9 technology to knock out the gene for CD5, a protein found on ...
The effectiveness of CAR T cell therapy against a variety of cancers, including solid tumors, could be boosted greatly by using CRISPR-Cas9 technology to knock out the gene for CD5, a protein found on ...
A phase 2 study to confirm safety and efficacy of MB-105, an autologous CD5-directed CAR T-cell therapy, in relapsed/refractory T-cell lymphoma (R/R TCL). This is an ASCO Meeting Abstract from the ...
PHILADELPHIA-- Knocking out a protein known to stifle T cell activation on CAR T cells using the CRISPR/Cas9 technology enhanced the engineered T cells' ability to eliminate blood cancers, according ...
MB-105, a CD5-targeted CAR-T cell therapy, has received FDA regenerative medicine advanced therapy designation for relapsed/refractory CD5-positive T-cell lymphoma. The designation aims to expedite ...
Scientists at the Washington University School of Medicine in St. Louis report that the difference between people who do and do not respond to immunotherapy may have to do with CD5 + dendritic cells ...
PHILADELPHIA – The effectiveness of CAR T cell therapy against a variety of cancers, including solid tumors, could be boosted greatly by using CRISPR-Cas9 technology to knock out the gene for CD5, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results